Portal:CPTAC/Hallmarks

From WikiPathways

(Difference between revisions)
Jump to: navigation, search
Current revision (18:59, 5 October 2017) (view source)
(added Therapeutics category)
 
(6 intermediate revisions not shown.)
Line 1: Line 1:
-
{| style="margin: 10px; background-color:#eaf2ee"
+
{| style="width:100%; margin: 10px; background-color:#eaf2ee"
-
|width=100px; cell padding=50px; style="text-align:center;"|'''Sustaining proliferative signaling''' {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:CPTAC/Hallmark/Proliferative}} View all [[Portal:CPTAC/Hallmark/Proliferative|hallmark pathways]]
+
|width=100px; cell padding=50px; style="text-align:center;"|[[Portal:CPTAC/Hallmark/Proliferative|<big><u><b>Sustaining proliferative signaling</b></u></big>]] {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:CPTAC/Hallmark/Proliferative}}
-
|width=100px; style="text-align:center;"|'''Evading growth suppressors'''{{#pwImage:Pathway:WP3972|250px||PDGFR-beta pathway}}
+
|width=100px; style="text-align:center;"|[[Portal:CPTAC/Hallmark/Growth|<big><u><b>Evading growth suppressors</b></u></big>]] {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:CPTAC/Hallmark/Growth}}
-
|width=100px; style="text-align:center;"|'''Activating invasion and metastasis''' {{#pwImage:Pathway:WP2828|250px||Bladder Cancer}}
+
|width=100px; style="text-align:center;"|[[Portal:CPTAC/Hallmark/Invasion|<big><u><b>Activating invasion and metastasis</b></u></big>]] {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:CPTAC/Hallmark/Invasion}}
-
|width=100px; style="text-align:center;"|'''Enabling replicative immortality''' {{#pwImage:Pathway:WP581|250px||EPO Receptor Signaling}}
+
|-
|-
-
|width=100px|{{#pwImage:Pathway:WP673|250px||ErbB Signaling Pathway}}
+
|width=100px; style="text-align:center;"|[[Portal:CPTAC/Hallmark/immortality|<big><u><b>Enabling replicative immortality</b></u></big>]] {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:CPTAC/Hallmark/immortality}}
-
|width=100px|{{#pwImage:Pathway:WP585|250px||Interferon type I signaling pathways}}
+
|width=100px; style="text-align:center;"|[[Portal:CPTAC/Hallmark/Angiogenesis|<big><u><b>Inducing angiogenesis</b></u></big>]] {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:CPTAC/Hallmark/Angiogenesis}}
-
|width=100px|{{#pwimage:Pathway:WP3|250px||Transcriptional activation by NRF2}}
+
|width=100px; style="text-align:center;"|[[Portal:CPTAC/Hallmark/Resisting|<big><u><b>Resisting cell death</b></u></big>]] {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:CPTAC/Hallmark/Resisting}}
-
|width=100px|{{#pwimage:Pathway:WP4018|250px||Pathways in Renal Cancer}}
+
|-
 +
|width=100px; style="text-align:center;"|[[Portal:CPTAC/Hallmark/Deregulating|<big><u><b>Deregulating cellular energetics</b></u></big>]] {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:CPTAC/Hallmark/Deregulating}}
 +
|width=100px; style="text-align:center;"|[[Portal:CPTAC/Hallmark/Instability|<big><u><b>Genome instability and mutation</b></u></big>]] {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:CPTAC/Hallmark/Instability}}
 +
|width=100px; style="text-align:center;"|[[Portal:CPTAC/Hallmark/Inflammation|<big><u><b>Tumor promoting inflammation</b></u></big>]] {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:CPTAC/Hallmark/Inflammation}}
 +
|-
 +
|width=100px; style="text-align:center;"|[[Portal:CPTAC/Hallmark/Avoiding|<big><u><b>Avoiding immune destruction</b></u></big>]] {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:CPTAC/Hallmark/Avoiding}}
 +
|width=100px; style="text-align:center;"|[[Portal:CPTAC/Hallmark/Therapeutics|<big><u><b>Therapeutics</b></u></big>]] {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:CPTAC/Hallmark/Therapeutics}}
|}
|}

Current revision

Sustaining proliferative signaling

EPO receptor signaling (Homo sapiens)

Image does not exist
EPO receptor signaling
Evading growth suppressors

Ultraconserved region 339 modulation of tumor suppressor microRNAs in cancer (Homo sapiens)

Image does not exist
Ultraconserved region 339 modulation of tumor suppressor microRNAs in cancer
Activating invasion and metastasis

H19, Rb-E2F1, and CDK-beta-catenin in colorectal cancer (Homo sapiens)

Image does not exist
H19, Rb-E2F1, and CDK-beta-catenin in colorectal cancer
Enabling replicative immortality

Wnt signaling (Homo sapiens)

Image does not exist
Wnt signaling
Inducing angiogenesis

VEGFA-VEGFR2 signaling (Homo sapiens)

Image does not exist
VEGFA-VEGFR2 signaling
Resisting cell death

Apoptosis (Homo sapiens)

Image does not exist
Apoptosis
Deregulating cellular energetics

TCA cycle nutrient use and invasiveness of ovarian cancer (Homo sapiens)

Image does not exist
TCA cycle nutrient use and invasiveness of ovarian cancer
Genome instability and mutation

Nucleotide excision repair (Homo sapiens)

Image does not exist
Nucleotide excision repair
Tumor promoting inflammation

Cytokines and inflammatory response (Homo sapiens)

Image does not exist
Cytokines and inflammatory response
Avoiding immune destruction

Type II interferon signaling (Homo sapiens)

Image does not exist
Type II interferon signaling
Therapeutics

Imatinib and chronic myeloid leukemia (Homo sapiens)

Image does not exist
Imatinib and chronic myeloid leukemia
Personal tools